anatibant

Anatibant is a potent and selective small-molecule antagonist of the bradykinin B2 receptor. It was developed for the treatment of traumatic brain injury (TBI). Anatibant is a non-peptide compound that crosses the blood-brain barrier and has been shown in preclinical models to reduce brain edema formation, intracranial hypertension, and histopathological damage following experimental TBI. Its mechanism of action involves inhibiting bradykinin from binding to the B2 receptor, thereby reducing vascular permeability and subsequent post-traumatic brain edema. Clinical development reached Phase 2 trials but was discontinued. The drug was originally developed by Xytis and Fournier[1][3][4][5][7].

Other names

anatibant mesilate